WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power Surmodics buys Alta Biomed for its PzF coating and a Carlsbad blood loop lab FDA names the first five companies in its READI-Home readmissions program CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first Edwards wins FDA approval for a pulmonary valve that expands from 13 mm to 22 mm Medtronic wins a Category I CPT code for renal denervation, effective January 2028 Axogen closes the BioCircuit deal and puts $34M of 2027 revenue on NerveTape BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power Surmodics buys Alta Biomed for its PzF coating and a Carlsbad blood loop lab FDA names the first five companies in its READI-Home readmissions program CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first Edwards wins FDA approval for a pulmonary valve that expands from 13 mm to 22 mm Medtronic wins a Category I CPT code for renal denervation, effective January 2028 Axogen closes the BioCircuit deal and puts $34M of 2027 revenue on NerveTape

Acquisition

Axogen closes the BioCircuit deal and puts $34M of 2027 revenue on NerveTape

MedDevice Startups Staff · 4 days ago · 2 min read · Via Axogen

Axogen closed its acquisition of BioCircuit Technologies on October 1, three weeks after agreeing to pay $200M in cash. The deal brings in NerveTape, which Axogen calls the first FDA cleared device for repairing transected peripheral nerves without sutures.

Axogen expects BioCircuit to contribute about $6M to fourth quarter 2026 revenue and about $34M in 2027. The Atlanta company also brings biomaterials work, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation.

Guiding $34M off an acquired device in its first full year is an aggressive number for a product whose competition is a technique rather than another product. Microsuturing costs nothing on the invoice, so the sales case has to be made in operating room minutes and in surgeon training time.

Questions & Answers

How much did Axogen pay for BioCircuit Technologies?

Axogen agreed to pay $200M in cash for BioCircuit Technologies, announced September 10, 2026. The acquisition closed on October 1, 2026.

What is BioCircuit Technologies' NerveTape device?

NerveTape is a device for repairing transected peripheral nerves without sutures. Axogen describes it as the first FDA cleared device for sutureless nerve repair, and acquired it when the BioCircuit Technologies deal closed on October 1, 2026.

How much revenue does Axogen expect from BioCircuit Technologies?

Axogen expects BioCircuit Technologies to add about $6M to its fourth quarter 2026 revenue and about $34M to 2027 revenue.

← Back to M&A